Mauricio Orrego is a Gastroenterology physician. OpenAlex indexes 21 publications with 1,048 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5401 Old York Road
Klein Bldg Ste 509
Philadelphia, PA 19141
Telephone
215-456-4985Provider last certified this registry record 20 Jan 2023.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20255 payments
- Ipsen Biopharmaceuticals, IncProgram year20254 payments
- Boston Scientific CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
36.2%Rifamycin Antibacterial13.1%Xifaxan100%Part D≥11 patientsBile Acid12.5%Ursodiol100%Part D≥17 patients+ 2 more classes in this area
Cardiovascular
34.5%Loop diuretic14%Furosemide100%Part D≥24 patientsBeta blocker11.6%Carvedilol100%Part D≥19 patients+ 1 more class in this area
Cancer & immunology
14.4%Kinase inhibitor6.4%Everolimus100%Part D<11 patientsCalcineurin inhibitor5.7%Tacrolimus100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Mutaciones en el ORF de la polimerasa del virus de la hepatitis B en muestras de pacientes con infección crónica
Biomedica (INSTITUTO NACIONAL DE SALUD)
2026 - S5488 Atypical Presentation of Portal Vein Stenosis: Diagnosis 13 Years Post-Liver Transplantation
The American Journal of Gastroenterology
2025 - Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
Journal of Hepatology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”